Testing a Smart Medication Dispenser (Mobili®) to Help People With Chronic Conditions Take Their Medicine

Summary

Medication adherence is one of the biggest challenges faced by healthcare systems, especially among people with multiple chronic diseases who take several medications daily. Studies show that up to half of patients do not take their medication as prescribed, which can compromise treatment effectiveness, increase complications, and lead to waste of healthcare resources.

In this context, several solutions have been developed to help patients organize their therapy, such as dose administration aids (DAAs) used in pharmacies. However, many of these systems are manual, inflexible, or difficult to use.

This study is part of the MobiMAd@PT project, which will evaluate Mobili®, a portable digital medication dispenser developed in Norway. Mobili® allows patients to automatically receive the right medication at the right time and comes with a real-time monitoring system, enabling healthcare professionals to detect missed doses and provide timely support.

The main goal of this study is to assess the effectiveness of Mobili® in improving medication adherence among patients with polypharmacy in Portugal and to understand whether this type of technology can be useful and applicable in the context of Portuguese community pharmacies. Your participation will contribute to the development of new ways to manage health at home, with the support of pharmacists and technology.

Conditions

• Dose Administration Aids
• Medication Adherence
• Polypharmacy
• Technology in Health
• Diabetes
• Cardiovascular Diseases

Interventions

DEVICE

Independent use of the Mobili® Device by patients, overseen by pharmacists

After recruitment each participant will be subject to a type I medication review. After allocation to the intervention group, pharmacists will provide initial training to participants, and during the course of the intervention whenever necessary (e.g. when delivering the eDosette with the therapeutic regime). Pharmacists will prepare the eDosette in the pharmacy and deliver it directly to participants with no further intervention. Participants will receive the number of eDosettes their therapeutic regime allows, to minimize visits to the pharmacy. For the control group, pharmacists will also provide the number of DAAs the therapeutic regime allows. Upon finishing the intervention, a new type II medication review will be performed for all participants (intervention and control) and information related to their personal therapeutic regime will be provided, ensuring a safe exit of the study.

Sponsors & Collaborators

• CBIOS - Research Center for Biosciences & Health Technologies

  collaborator UNKNOWN

• MedThings

  collaborator UNKNOWN

• Associação Nacional das Farmácias

  collaborator UNKNOWN

• University of Oslo

  collaborator OTHER

• Universidade de Trás-os-Montes e Alto Douro

  collaborator UNKNOWN

• GHTM - Global Health and Tropical Medicine

  collaborator UNKNOWN

• COFAC Cooperativa de Formacao e Animacao Cultural CRL (Portugal)

  collaborator UNKNOWN

• Lusofona University

  lead OTHER

Principal Investigators

• João Pedro B Gregório, PharmD PhD · COFAC - Cooperativa Cooperativa de Animação e Formação Cultural, C.R.L

Study Design

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-10-15

Primary Completion

2026-04-15

Completion

2026-06-30

Countries

• Portugal

Study Locations